These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25140280)

  • 21. [A clinical and molecular study of long-term survival glioblastomas].
    Wang X; Liu YH; Xie F; You C; Mao Q
    Zhonghua Wai Ke Za Zhi; 2013 Feb; 51(2):166-70. PubMed ID: 23711013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
    Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
    Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
    Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
    World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases.
    Kim HR; Lee JJ; Lee JI; Nam DH; Suh YL; Seol HJ
    J Korean Neurosurg Soc; 2016 Jan; 59(1):44-51. PubMed ID: 26885285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
    Appin CL; Gao J; Chisolm C; Torian M; Alexis D; Vincentelli C; Schniederjan MJ; Hadjipanayis C; Olson JJ; Hunter S; Hao C; Brat DJ
    Brain Pathol; 2013 Jul; 23(4):454-61. PubMed ID: 23289977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
    J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
    Wiencke JK; Aldape K; McMillan A; Wiemels J; Moghadassi M; Miike R; Kelsey KT; Patoka J; Long J; Wrensch M
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1774-83. PubMed ID: 16030116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
    Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
    Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas.
    Yang SH; Kim YH; Kim JW; Park CK; Park SH; Jung HW
    J Korean Neurosurg Soc; 2009 Oct; 46(4):385-8. PubMed ID: 19893731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.
    Pasini A; Iorio P; Bianchi E; Cerasoli S; Cremonini AM; Faedi M; Guarnieri C; Guiducci G; Riccioni L; Molinari C; Rengucci C; Calistri D; Giordano E
    Oncol Rep; 2012 Dec; 28(6):2271-7. PubMed ID: 22992787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
    Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S
    Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.